NASDAQ:SGEN Seagen (SGEN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$228.74▼$228.7450-Day Range$228.74▼$228.7452-Week Range$123.77▼$228.96Volume86 shsAverage Volume1.48 million shsMarket Capitalization$42.93 billionP/E RatioN/ADividend YieldN/APrice Target$229.00 Stock AnalysisStock Analysis Get Seagen alerts: Email Address Seagen MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.1% Upside$229.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.86Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.82) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.42 out of 5 starsMedical Sector900th out of 936 stocksBiotechnology Industry8th out of 11 stocks 1.0 Analyst's Opinion Consensus RatingSeagen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSeagen has received no research coverage in the past 90 days.Read more about Seagen's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SGEN. Previous Next 0.0 Dividend Strength Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeagen has received a 13.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Brentuximab vedotin", "Enfortumab vedotin", and "Tucatinib" products. See details.Environmental SustainabilityThe Environmental Impact score for Seagen is -2.86. Previous Next N/A News and Social Media Coverage Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Seagen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($3.82) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 15.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Seagen Stock (NASDAQ:SGEN)Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here SGEN Stock News HeadlinesMay 27, 2024 | seekingalpha.comPfizer: Turning The Corner (Rating Upgrade)April 13, 2024 | wsj.comTwo Brothers, a Big Biotech Bet and an $8 Billion PayoutJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."March 20, 2024 | msn.comRon Baron Portfolio Magic: Building Your Financial FutureMarch 13, 2024 | msn.comBailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving marketsMarch 1, 2024 | bizjournals.comPfizer shutting down Seagen's $350M construction project in EverettFebruary 24, 2024 | finance.yahoo.comNeuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk SaysFebruary 23, 2024 | finance.yahoo.comMRNA Feb 2024 64.000 putJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."February 23, 2024 | finance.yahoo.comMRNA Feb 2024 77.000 callFebruary 23, 2024 | msn.comPfizer adds bull at Guggenheim on ex-COVID prospectsFebruary 22, 2024 | finance.yahoo.comMRNA Feb 2024 67.000 putFebruary 12, 2024 | msn.comPfizer touts cancer efforts in first Super Bowl commercialFebruary 10, 2024 | finance.yahoo.comPRIMECAP Management's Strategic Exits and New Positions Highlight Q4 MovesJanuary 29, 2024 | msn.comPfizer Q4 results on deck amid gloomy earnings outlookJanuary 28, 2024 | za.investing.comPro Research: Wall Street eyes Seagen's growth trajectoryDecember 30, 2023 | ca.finance.yahoo.comSGEN Jan 2024 210.000 putDecember 30, 2023 | ca.finance.yahoo.comSGEN Jan 2024 235.000 put(CONTRSee More Headlines Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees3,256Year Founded1998Price Target and Rating Average Stock Price Target$229.00 High Stock Price Target$229.00 Low Stock Price Target$229.00 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-610,310,000.00 Net Margins-32.61% Pretax Margin-32.12% Return on Equity-28.06% Return on Assets-20.92% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.12 Sales & Book Value Annual Sales$2.30 billion Price / Sales18.66 Cash FlowN/A Price / Cash FlowN/A Book Value$15.10 per share Price / Book15.15Miscellaneous Outstanding Shares187,698,000Free Float139,084,000Market Cap$42.93 billion OptionableOptionable Beta0.32 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. David R. Epstein B.Sc. (Age 61)M.B.A., CEO & Director Comp: $1.39MMr. Todd E. Simpson (Age 62)Chief Financial Officer Comp: $1.26MDr. Vaughn B. Himes Ph.D. (Age 62)Chief Technical Officer Comp: $1.08MMs. Jean I. Liu J.D. (Age 55)M.S., Chief Legal Officer & Corporate Secretary Comp: $1.23MMr. Charles R. Romp (Age 55)Executive Vice President of Commercial U.S. Comp: $1.08MDr. Roger D. Dansey M.D. (Age 67)Chief Medical Officer and President of Research & Development Comp: $2.48MMr. William ComptonSenior VP of Global Information Technology & CIOMr. David CaouetteVice President of Corporate CommunicationsMr. Matt SkeltonVice President of MarketingMs. Peggy M. PinkstonChief Human Resources OfficerMore ExecutivesKey CompetitorsBio-TechneNASDAQ:TECHQiagenNYSE:QGENCRISPR TherapeuticsNASDAQ:CRSPDenali TherapeuticsNASDAQ:DNLISpectrum PharmaceuticalsNASDAQ:SPPIView All CompetitorsInsiders & InstitutionsCapital Markets Trading UK LLPSold 106,200 shares on 5/15/2024Ownership: 0.000%David R EpsteinSold 10,620 sharesTotal: $2.26 M ($213.01/share)Vaughn B HimesSold 8,785 sharesTotal: $1.87 M ($213.32/share)Roger D DanseySold 71 sharesTotal: $14,661.50 ($206.50/share)Charles R RompSold 45 sharesTotal: $9,292.50 ($206.50/share)View All Institutional Transactions Should I Buy Seagen Stock? SGEN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Seagen Inc.: Seagen Inc. has shown a positive Month-to-Month Change Percentage in short interest, indicating potential stability. The institutional ownership percentage is high at 91.8%, suggesting confidence from large investors. Seagen Inc. has a strong Fifty-Two Week Performance, showcasing consistent growth over the past year. The company's Average Daily Volume is significant at 1,370,000 shares, indicating active trading and liquidity. With a Price on Record Date of $198, the stock price is relatively high, potentially reflecting positive market sentiment. Cons Investors should be bearish about investing in Seagen Inc. for these reasons: Seagen Inc. has a relatively high Days to Cover ratio of 4.1, which may indicate a longer time for short sellers to close their positions. There has been a slight decrease in Shares Shorted from the previous month, which could suggest a shift in market sentiment. The Short Percentage of Float is 0, which may indicate limited short-term trading opportunities. The Float Size is 0, which could impact the stock's volatility and liquidity in the market. Despite positive aspects, investors should consider the potential risks associated with the stock's performance. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, July 5, 2024. Please send any questions or comments about these Seagen pros and cons to contact@marketbeat.com. SGEN Stock Analysis - Frequently Asked Questions How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The firm's revenue for the quarter was up 27.1% on a year-over-year basis. What is Clay B. Siegall's approval rating as Seagen's CEO? 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Does Seagen have any subsidiaries? Seagen subsidiaries include Cascadian Therapeutics. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM) and Tesla (TSLA). This page (NASDAQ:SGEN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
